these effects may be compounded by similar reductions observed after chronic treatment with ethanol (Lopez-Moreno et al., 2008). These data suggest that the enhancement of ethanol-seeking following the administration of CB1 agonists during periods of abstinence may be due to a blunted DA release in the NAc above and beyond that observed in subjects that only receive ethanol. However, all of these studies have employed non-contingent treatment with WIN, and it would be useful to determine if rotating schedules of WIN and ethanol self-administration can produce similar effects. Pending the outcome of these studies, these results may have implications for the understanding and treatment of co-morbid CUDs and AUDs.
